[Treatment of arterial hypertension. Clinico-therapeutical aspects of a new association: potassium cancreonate of altizide-rescinnamine].
D000328:Adult; D000368:Aged; D000737:Androstenols / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D012110:Reserpine / Q000627:therapeutic use; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use*
D000737:Androstenols; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D004338:Drug Combinations; D000451:Mineralocorticoid Receptor Antagonists; D046948:Secologanin Tryptamine Alkaloids; D049993:Sodium Chloride Symporter Inhibitors; D012110:Reserpine
Il trattamento dell'ipertensione arteriosa. Aspetti clinico-terapeutici di una nuova associazione: canrenoato di K-altizide-rescinnamina.